Organic Carbamates in Drug Design and Medicinal Chemistry

Journal of Medicinal Chemistry

Volumn 58, Issue 7, 2015, Pages 2895-2940

  Ghosh, Arun K ^a   Brindisi, Margherita ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; AMPRENAVIR; ATAZANAVIR; BETA SECRETASE INHIBITOR; CARBAMIC ACID DERIVATIVE; CARBONIC ACID DERIVATIVE; EFAVIRENZ; ENTINOSTAT; ETHER DERIVATIVE; FELBAMATE; FLUPIRTINE; GAMMA SECRETASE INHIBITOR; MEBENDAZOLE; MITOMYCIN; MURAGLITAZAR; ORGANIC COMPOUND; PRODRUG; RETIGABINE; RITONAVIR; RIVASTIGMINE; ROXIFIBAN; ZAFIRLUKAST; ANTIVIRUS AGENT; CYSTEINE PROTEINASE INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NS-5 PROTEIN, HEPATITIS C VIRUS; P16 PROTEASE, HUMAN IMMUNODEFICIENCY VIRUS 1; SECRETASE; SERINE PROTEINASE INHIBITOR; VIRUS PROTEIN;

CURTIUS REARRANGEMENT; DRUG DESIGN; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; MEDICINAL CHEMISTRY; NONHUMAN; REVIEW; SOLID PHASE SYNTHESIS; ANTAGONISTS AND INHIBITORS; CHEMISTRY; HEPATITIS C; PROCEDURES; SYNTHESIS;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANTIVIRAL AGENTS; CARBAMATES; CHEMISTRY TECHNIQUES, SYNTHETIC; CHEMISTRY, PHARMACEUTICAL; CYSTEINE PROTEINASE INHIBITORS; DRUG DESIGN; DRUG STABILITY; HEPATITIS C; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; PRODRUGS; SERINE PROTEINASE INHIBITORS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84927586797     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501371s     Document Type: Review

References (351)

1. Conradi, R. A.; Hilgers, A. R.; Ho, N. F.; Burton, P. S. The influence of peptide structure on transport across Caco-2 cells. II. Peptide bond modification which results in improved permeability Pharm. Res. 1992, 9, 435 - 439
2. Nielsen, P. E. Pseudo-peptides in Drug Discovery; Wiley-VCH: Weinheim, Germany, 2004.
3. Sewald, N.; Jakubke, H.-D. Peptides: Chemistry and Biology; Wiley-VCH: Weinheim, Germany, 2002.
4. Vagner, J.; Qu, H.; Hruby, V. J. Peptidomimetics, a synthetic tool of drug discovery Curr. Opin. Chem. Biol. 2008, 12, 292 - 296
5. Nowick, J. S. What I have learned by using chemical model systems to study biomolecular structure and interactions Org. Biomol. Chem. 2006, 4, 3869 - 3885
6. Liskamp, R. M.; Rijkers, D. T.; Kruijtzer, J. A.; Kemmink, J. Peptides and proteins as a continuing exciting source of inspiration for peptidomimetics ChemBioChem 2011, 12, 1626 - 1653
7. Fletcher, M. D.; Campbell, M. M. Partially modified retro-inverso peptides: development, synthesis, and conformational behavior Chem. Rev. 1998, 98, 763 - 796
8. Patil, B. S.; Vasanthakumar, G. R.; Suresh Babu, V. V. Isocyanates of N alpha-[(9-fluorenylmethyl)oxy]carbonyl amino acids: synthesis, isolation, characterization, and application to the efficient synthesis of urea peptidomimetics J. Org. Chem. 2003, 68, 7274 - 7280
9. Sureshbabu, V. V.; Patil, B. S.; Venkataramanarao, R. Preparation, isolation, and characterization of Nalpha-Fmoc-peptide isocyanates: solution synthesis of oligo-alpha-peptidyl ureas J. Org. Chem. 2006, 71, 7697 - 7705
10. Semetey, V.; Hemmerlin, C.; Didierjean, C.; Schaffner, A. P.; Giner, A. G.; Aubry, A.; Briand, J. P.; Marraud, M.; Guichard, G. Unexpected stability of the urea cis-trans isomer in urea-containing model pseudopeptides Org. Lett. 2001, 3, 3843 - 3846
11. Myers, A. C.; Kowalski, J. A.; Lipton, M. A. Facile incorporation of urea pseudopeptides into protease substrate analogue inhibitors Bioorg. Med. Chem. Lett. 2004, 14, 5219 - 5222
12. Fischer, L.; Didierjean, C.; Jolibois, F.; Semetey, V.; Manuel Lozano, J.; Briand, J. P.; Marraud, M.; Poteau, R.; Guichard, G. Propensity for local folding induced by the urea fragment in short-chain oligomers Org. Biomol. Chem. 2008, 6, 2596 - 2610
13. Cho, C. Y.; Moran, E. J.; Cherry, S. R.; Stephans, J. C.; Fodor, S. P.; Adams, C. L.; Sundaram, A.; Jacobs, J. W.; Schultz, P. G. An unnatural biopolymer Science 1993, 261, 1303 - 1305
14. Sureshbabu, V. V.; Venkataramanarao, R.; Naik, S. A.; Chennakrishnareddy, G. Synthesis of tetrazole analogues of amino acids using Fmoc chemistry: isolation of amino free tetrazoles and their incorporation into peptides Tetrahedron Lett. 2007, 48, 7038 - 7041
15. Sureshbabu, V. V.; Hemantha, H. P.; Naik, S. A. Synthesis of 1,2,4-oxadiazole-linked orthogonally urethane-protected dipeptide mimetics Tetrahedron Lett. 2008, 49, 5133 - 5136
16. Dibenedetto, A.; Aresta, M.; Fragale, C.; Narracci, M. Reaction of silylalkylmono- and silylalkyldi-amines with carbon dioxide: evidence of formation of inter- and intra-molecular ammonium carbamates and their conversion into organic carbamates of industrial interest under carbon dioxide catalysis Green Chem. 2002, 4, 439 - 443
17. Gupte, S. P.; Shivarkar, A. B.; Chaudhari, R. V. Carbamate synthesis by solid-base catalyzed reaction of disubstituted ureas and carbonates Chem. Commun. 2001, 2620 - 2621
18. Martin, L. L.; Davis, L.; Klein, J. T.; Nemoto, P.; Olsen, G. E.; Bores, G. M.; Camacho, F.; Petko, W. W.; Rush, D. K.; Selk, D.; Smith, C. P.; Vargas, H. M.; Winslow, J. T.; Effland, R. C.; Fink, D. M. Synthesis and preliminary structure-activity relationships of 1-[(3-fluoro-4-pyridinyl)amino]-3-methyl-1 H -indol-5-yl methyl carbamate (P10358), a novel acetylcholinesterase inhibitor Bioorg. Med. Chem. Lett. 1997, 7, 157 - 162
19. Wuts, P. G. M.; Greene, T. W. Protective Groups in Organic Synthesis, 4 th ed.; Wiley: Hoboken, NJ, 2006.
20. Cox, C.; Lectka, T. Solvent effects on the barrier to rotation in carbamates J. Org. Chem. 1998, 63, 2426 - 2427
21. Rablen, P. R. Computational analysis of the solvent effect on the barrier to rotation about the conjugated C-N bond in methyl N, N -dimethylcarbamate J. Org. Chem. 2000, 65, 7930 - 7937
22. Moraczewski, A. L.; Banaszynski, L. A.; From, A. M.; White, C. E.; Smith, B. D. Using hydrogen bonding to control carbamate C-N rotamer equilibria J. Org. Chem. 1998, 63, 7258 - 7262
23. Dugave, C.; Demange, L. Cis-trans isomerization of organic molecules and biomolecules: implications and applications Chem. Rev. 2003, 103, 2475 - 2532
24. Wiberg, K. B.; Bailey, W. F. Dipole-stabilized carbanions: a computational study of N -methylformamide anion and methyl N -methylcarbamate anion J. Org. Chem. 2002, 67, 5365 - 5368
25. Deetz, M. J.; Forbes, C. C.; Jonas, M.; Malerich, J. P.; Smith, B. D.; Wiest, O. Unusually low barrier to carbamate C-N rotation J. Org. Chem. 2002, 67, 3949 - 3952
26. Kaur, D.; Sharma, P.; Bharatam, P. V. Amide resonance in thio- and seleno- carbamates: a theoretical study J. Mol. Struct.: THEOCHEM 2005, 757, 149 - 153
27. Lauvergnat, D.; Hiberty, P. C. Role of conjugation in the stabilities and rotational barriers of formamide and thioformamide. An ab initio valence-bond study J. Am. Chem. Soc. 1997, 119, 9478 - 9482
28. Marcovici-Mizrahi, D.; Gottlieb, H. E.; Marks, V.; Nudelman, A. On the stabilization of the syn-rotamer of amino acid carbamate derivatives by hydrogen bonding J. Org. Chem. 1996, 61, 8402 - 8406
29. Lee, C. M.; Kumler, W. D. The dipole moment and structure of the carbamate group J. Am. Chem. Soc. 1961, 83, 4596 - 4600
30. Dugave, C. Chemical aspects of the restricted rotation of esters, amides, and related compounds. In Cis-trans Isomerization in Biochemistry; Dugave, C., Ed.; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2006; pp 143 - 166.
31. Testa, B.; Mayer, J. M. Hydrolysis in Drug and Prodrug Metabolism-Chemistry, Biochemistry, and Enzymology; Wiley-VCH: Weinheim, Germany, 2003.
32. Vacondio, F.; Silva, C.; Mor, M.; Testa, B. Qualitative structure-metabolism relationships in the hydrolysis of carbamates Drug Metab. Rev. 2010, 42, 551 - 589
33. Tarzia, G.; Duranti, A.; Tontini, A.; Piersanti, G.; Mor, M.; Rivara, S.; Plazzi, P. V.; Park, C.; Kathuria, S.; Piomelli, D. Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors J. Med. Chem. 2003, 46, 2352 - 2360
34. Burk, M. J.; Allen, J. G. A mild amide to carbamate transformation J. Org. Chem. 1997, 62, 7054 - 7057
35. Matsumura, Y.; Maki, T.; Satoh, Y. Electrochemically induced Hofmann rearrangement Tetrahedron Lett. 1997, 38, 8879 - 8882
36. Gogoi, P.; Konwar, D. An efficient modification of the Hofmann rearrangement: synthesis of methyl carbamates Tetrahedron Lett. 2007, 48, 531 - 533
37. Curtius, T. Hydrazide und azide organischer säuren I. Abhandlung J. Prakt. Chem. 1894, 50, 275 - 294
38. Scriven, E. F. V.; Turnbull, K. Azides: their preparation and synthetic uses Chem. Rev. 1988, 88, 297 - 368
39. Cenini, S.; Crotti, C.; Pizzotti, M.; Porta, F. Ruthenium carbonyl catalyzed reductive carbonylation of aromatic nitro-compounds-a selective route to carbamates J. Org. Chem. 1988, 53, 1243 - 1250
40. Salvatore, R. N.; Ledger, J. A.; Jung, K. W. An efficient one-pot synthesis of N-alkyl carbamates from primary amines using Cs2CO3 Tetrahedron Lett. 2001, 42, 6023 - 6025
41. Waldman, T. E.; Mcghee, W. D. Isocyanates from primary amines and carbon-dioxide-dehydration of carbamate anions J. Chem. Soc., Chem. Commun. 1994, 957 - 958
42. Darensbourg, D. J.; Niezgoda, S. A.; Draper, J. D.; Reibenspies, J. H. Mechanistic aspects of the copolymerization of CO2 and epoxides by soluble zinc bis(phenoxide) catalysts as revealed by their cadmium analogues J. Am. Chem. Soc. 1998, 120, 4690 - 4698
43. Sakakura, T.; Saito, Y.; Okano, M.; Choi, J. C.; Sako, T. Selective conversion of carbon dioxide to dimethyl carbonate by molecular catalysis J. Org. Chem. 1998, 63, 7095 - 7096
44. Yoshida, M.; Hara, N.; Okuyama, S. Catalytic production of urethanes from amines and alkyl halides in supercritical carbon dioxide Chem. Commun. 2000, 151 - 152
45. Salvatore, R. N.; Chu, F. X.; Nagle, A. S.; Kapxhiu, E. A.; Cross, R. M.; Jung, K. W. Efficient Cs2CO3-promoted solution and solid phase synthesis of carbonates and carbamates in the presence of TBAI Tetrahedron 2002, 58, 3329 - 3347
46. Senanayake, C. H.; Fredenburgh, L. E.; Reamer, R. A.; Larsen, R. D.; Verhoeven, T. R.; Reider, P. J. Nature of N -bromosuccinimide in basic-media-the true oxidizing species in the Hofmann rearrangement J. Am. Chem. Soc. 1994, 116, 7947 - 7948
47. Moriarty, R. M.; Chany, C. J.; Vaid, R. K.; Prakash, O.; Tuladhar, S. M. Preparation of methyl carbamates from primary alkylcarboxamides and arylcarboxamides using hypervalent iodine J. Org. Chem. 1993, 58, 2478 - 2482
48. Radlick, P.; Brown, L. R. A versatile modification of the Hofmann rearrangement Synthesis 1974, 4, 290 - 292
49. Huang, X. C.; Keillor, J. W. Preparation of methyl carbamates via a modified Hofmann rearrangement Tetrahedron Lett. 1997, 38, 313 - 316
50. Baumgarten, H. E.; Smith, H. L.; Staklis, A. Reactions of amines. XVIII. Oxidative rearrangement of amides with lead tetraacetate J. Org. Chem. 1975, 40, 3554 - 3561
51. Kajigaeshi, S.; Asano, K.; Fujisaki, S.; Kakinami, T.; Okamoto, T. Oxidation using quaternary ammonium polyhalides 0.1. An efficient method for the Hofmann degradation of amides by use of benzyltrimethylammonium tribromide Chem. Lett. 1989, 3, 463 - 464
52. Erhardt, P. W. Curtius conversion of acids to amines under neutral conditions via an anthrylmethyl carbamate J. Org. Chem. 1979, 44, 883 - 884
53. Yamatsugu, K.; Kamijo, S.; Suto, Y.; Kanai, M.; Shibasaki, M. A concise synthesis of Tamiflu: third generation route via the Diels-Alder reaction and the Curtius rearrangement Tetrahedron Lett. 2007, 48, 1403 - 1406
54. Overman, L. E.; Taylor, G. F.; Petty, C. B.; Jessup, P. J. trans -1- N -Acylamino-1,3-dienes: preparation from dienoic acids J. Org. Chem. 1978, 43, 2164 - 2167
55. Dussault, P. H.; Xu, C. Curtius rearrangement and Wolff homologation of functionalized peroxides Tetrahedron Lett. 2004, 45, 7455 - 7457
56. Jean, L.; Baglin, I.; Rouden, J.; Maddaluno, J.; Lasne, M. C. A convenient route to 1-benzyl 3-aminopyrrolidine and 3-aminopiperidine Tetrahedron Lett. 2001, 42, 5645 - 5649
57. Koza, G.; Ozcan, S.; Sahin, E.; Balci, M. Regioselective synthesis of the 3,4-dihydrofuro[3,2-d]pyrimidin-2(1 H)-one skeleton: a new class of compound Tetrahedron 2009, 65, 5973 - 5976
58. Ma, D.; Sun, H. General route to 2,4,5-trisubstituted piperidines from enantiopure β-amino esters. Total synthesis of Pseudodistomin B triacetate and Pseudodistomin F J. Org. Chem. 2000, 65, 6009 - 6016
59. Migawa, M. T.; Swayze, E. E. A solid-phase synthesis of N, N ′-disubstituted ureas and perhydroimidazo[1,5-a]pyrazines via the Curtius rearrangement Org. Lett. 2000, 2, 3309 - 3311
60. Wolff, O.; Waldvogel, S. R. Reliable protocol for the large scale synthesis of diphenylphosphoryl azide (DPPA) Synthesis 2004, 1303 - 1305
61. Nowick, J. S.; Powell, N. A.; Nguyen, T. M.; Noronha, G. An improved method for the synthesis of enantiomerically pure amino-acid ester isocyanates J. Org. Chem. 1992, 57, 7364 - 7366
62. Majer, P.; Randad, R. S. A safe and efficient method for preparation of N, N ′-unsymmetrically disubstituted ureas utilizing triphosgene J. Org. Chem. 1994, 59, 1937 - 1938
63. Batey, R. A.; Santhakumar, V.; Yoshina-Ishii, C.; Taylor, S. D. An efficient new protocol for the formation of unsymmetrical tri- and tetrasubstituted ureas Tetrahedron Lett. 1998, 39, 6267 - 6270
64. Ozaki, S. Recent advances in isocyanate chemistry Chem. Rev. 1972, 72, 457 - 496
65. Abla, M.; Chol, J. C.; Sakakura, T. Halogen-free process for the conversion of carbon dioxide to urethanes by homogeneous catalysis Chem. Commun. 2001, 2238 - 2239
66. Yoshida, Y.; Ishii, S.; Yamashita, T. A direct synthesis of carbamate ester from carbon dioxide, amine and alkyl halide Chem. Lett. 1984, 13, 1571 - 1572
67. Kim, J. G.; Jang, D. O. Indium-catalyzed reaction for the synthesis of carbamates and carbonates: selective protection of amino groups Tetrahedron Lett. 2009, 50, 2688 - 2692
68. Matassa, V. G.; Maduskuie, T. P., Jr.; Shapiro, H. S.; Hesp, B.; Snyder, D. W.; Aharony, D.; Krell, R. D.; Keith, R. A. Evolution of a series of peptidoleukotriene antagonists: synthesis and structure/activity relationships of 1,3,5-substituted indoles and indazoles J. Med. Chem. 1990, 33, 1781 - 1790
69. Roberts, N. A.; Martin, J. A.; Kinchington, D.; Broadhurst, A. V.; Craig, J. C.; Duncan, I. B.; Galpin, S. A.; Handa, B. K.; Kay, J.; Krohn, A.; Lambert, R. W.; Merrett, J. H.; Mills, J. S.; Parkes, K. E. B.; Redshaw, S.; Ritchie, A. J.; Taylor, D. L.; Thomas, G. J.; Machin, P. J. Rational design of peptide-based HIV proteinase inhibitors Science 1990, 248, 358 - 361
70. Eckert, H.; Forster, B. Triphosgene, a crystalline phosgene substitute Angew. Chem., Int. Ed. Engl. 1987, 26, 894 - 895
71. Denarié, M.; Grehouillat, D.; Malfroot, T.; Senet, J. P.; Sennyey, G.; Wolf, P. 2,2′-Carbonyl-bis(3,5-dioxo-4-methyl-1,2,4-oxadiazolidine): a new reagent for the preparation of carbamates and amides, application to the synthesis of dipeptides Tetrahedron Lett. 1987, 28, 5823 - 5826
72. Takeda, K.; Tsuboyama, K.; Yamaguchi, K.; Ogura, H. 1,1′-Bis[6-(trifluoromethyl)benzotriazolyl] oxalate (BTBO): a new reactive coupling reagent for the synthesis of dipeptides, esters, and thio esters J. Org. Chem. 1985, 50, 273 - 275
73. Kornblum, N.; Scott, A. A new method for protecting amines J. Org. Chem. 1977, 42, 399 - 400
74. Rosowsky, A.; Wright, J. E. N.omega.-Alkoxycarbonylation of.alpha.,.omega.-diamino acids with 2-(trimethylsilyl)ethyl 4-nitrophenyl carbonate J. Org. Chem. 1983, 48, 1539 - 1541
75. Dressman, B. A.; Spangle, L. A.; Kaldor, S. W. Solid phase synthesis of hydantoins using a carbamate linker and a novel cyclization/cleavage step Tetrahedron Lett. 1996, 37, 937 - 940
76. Rahmathullah, S. M.; Hall, J. E.; Bender, B. C.; McCurdy, D. R.; Tidwell, R. R.; Boykin, D. W. Prodrugs for amidines: synthesis and anti- Pneumocystis carinii activity of carbamates of 2,5-bis(4-amidinophenyl)furan J. Med. Chem. 1999, 42, 3994 - 4000
77. Ghosh, A. K.; Bilcer, G.; Schiltz, G. Syntheses of FDA approved HIV protease inhibitors Synthesis 2001, 2203 - 2229
78. Ghosh, A. K.; Chapsal, B. D.; Steffey, M.; Agniswamy, J.; Wang, Y. F.; Amano, M.; Weber, I. T.; Mitsuya, H. Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 2308 - 2311
79. Ghosh, A. K.; Gemma, S.; Simoni, E.; Baldridge, A.; Walters, D. E.; Ide, K.; Tojo, Y.; Koh, Y.; Amano, M.; Mitsuya, H. Synthesis and biological evaluation of novel allophenylnorstatine-based HIV-1 protease inhibitors incorporating high affinity P2-ligands Bioorg. Med. Chem. Lett. 2010, 20, 1241 - 1246
80. Ghosh, A. K.; Chapsal, B. D.; Baldridge, A.; Ide, K.; Koh, Y.; Mitsuya, H. Design and synthesis of stereochemically defined novel spirocyclic P2-ligands for HIV-1 protease inhibitors Org. Lett. 2008, 10, 5135 - 5138
81. Ogura, H.; Kobayashi, T.; Shimizu, K.; Kawabe, K.; Takeda, K. A novel active ester synthesis reagent (N, N ′-disuccinimidyl carbonate) Tetrahedron Lett. 1979, 20, 4745 - 4746
82. Ogura, H.; Sato, O.; Takeda, K. β-Elimination of β-hydroxyamino acids with disuccinimido carbonate Tetrahedron Lett. 1981, 22, 4817 - 4818
83. Takeda, K.; Tsuboyama, K.; Hoshino, M.; Kishino, M.; Ogura, H. A synthesis of a new type of alkoxycarbonylating reagents from 1,1-bis[6-(trifluoromethyl)benzotriazolyl] carbonate (BTBC) and their reactions Synthesis 1987, 557 - 560
84. Sunggak, K.; Jae, I. L.; Young, K. K. Di-2-pyridyl carbonate: a new efficient coupling agent for the direct esterification of carboxylic acids Tetrahedron Lett. 1984, 25, 4943 - 4946
85. Ghosh, A. K.; Duong, T. T.; McKee, S. P. Di(2-pyridyl) carbonate promoted alkoxycarbonylation of amines: a convenient synthesis of functionalized carbamates Tetrahedron Lett. 1991, 32, 4251 - 4254
86. Ghosh, A. K.; Doung, T. T.; McKee, S. P.; Thompson, W. J. N, N ′-Dissuccinimidyl carbonate: a useful reagent for alkoxycarbonylation of amines Tetrahedron Lett. 1992, 33, 2781 - 2784
87. Shute, R. E.; Rich, D. H. Synthesis and evaluation of novel activated mixed carbonate reagents for the introduction of the 2-(trimethylsilyl)ethoxycarbonyl(Teoc)-protecting group Synthesis 1987, 346 - 349
88. Corey, E. J.; Zhang, F. Y. re-and si -face-selective nitroaldol reactions catalyzed by a rigid chiral quaternary ammonium salt: a highly stereoselective synthesis of the HIV protease inhibitor Amprenavir (Vertex 478) Angew. Chem., Int. Ed. Engl. 1999, 38, 1931 - 1934
89. Ghosh, A. K.; Takayama, J. Enantioselective synthesis of cyclopentyltetrahydrofuran (Cp-THF), an important high-affinity P2-ligand for HIV-1 protease inhibitors Tetrahedron Lett. 2008, 49, 3409 - 3412
90. Ghosh, A. K.; Mckee, S. P.; Duong, T. T.; Thompson, W. J. An efficient synthesis of functionalized urethanes from azides J. Chem. Soc., Chem. Commun. 1992, 1308 - 1310
91. Park, Y. D.; Kim, H. K.; Kim, J. J.; Cho, S. D.; Kim, S. K.; Shiro, M.; Yoon, Y. J. N-Nitration of secondary amines with 4-chloro-5-methoxy-2-nitropyridazin-3-one J. Org. Chem. 2003, 68, 9113 - 9115
92. Lee, H. G.; Kim, M. J.; Park, S. E.; Kim, J. J.; Kim, B. R.; Lee, S. G.; Yoon, Y. J. Phenyl 4,5-dichloro-6-oxopyridazine-1(6 H)-carboxylate as carbonyl source: facile and selective synthesis of carbamates and ureas under mild conditions Synlett 2009, 2809 - 2814
93. Tsuda, T.; Watanabe, K.; Miyata, K.; Yamamoto, H.; Saegusa, T. Preparation and characterization of copper(I) amides Inorg. Chem. 1981, 20, 2728 - 2730
94. Inesi, A.; Mucciante, V.; Rossi, L. A convenient method for the synthesis of carbamate esters from amines and tetraethylammonium hydrogen carbonate J. Org. Chem. 1998, 63, 1337 - 1338
95. McGhee, W. D.; Riley, D. P.; Christ, M. E.; Christ, K. M. Palladium-catalyzed generation of O-allylic urethanes and carbonates from amines/alcohols, carbon dioxide, and allylic chlorides Organometallics 1993, 12, 1429 - 1433
96. Salvatore, R. N.; Flanders, V. L.; Ha, D.; Jung, K. W. Cs2CO3-promoted efficient carbonate and carbamate synthesis on solid phase Org. Lett. 2000, 2, 2797 - 2800
97. Salvatore, R. N.; Chu, F.; Nagle, A. S.; Kapxhiu, E. A.; Cross, R. M.; Jung, K. W. Efficient Cs2CO3-promoted solution and solid phase synthesis of carbonates and carbamates in the presence of TBAI Tetrahedron 2002, 58, 3329 - 3347
98. Abla, M.; Choi, J. C.; Sakakura, T. Halogen-free process for the conversion of carbon dioxide to urethanes by homogeneous catalysis Chem. Commun. 2001, 2238 - 2239
99. Abla, M.; Choi, J. C.; Sakakura, T. Nickel-catalyzed dehydrative transformation of CO2 to urethanes Green Chem. 2004, 6, 524 - 525
100. Peterson, S. L.; Stucka, S. M.; Dinsmore, C. J. Parallel synthesis of ureas and carbamates from amines and CO2 under mild conditions Org. Lett. 2010, 12, 1340 - 1343
101. Kodaka, M.; Tomohiro, T.; Okuno, H. The mechanism of the Mitsunobu reaction and its application to CO2 fixation J. Chem. Soc., Chem. Commun. 1993, 81 - 82
102. Ren, L.; Jiao, N. PdCl2 catalyzed efficient assembly of organic azides, CO, and alcohols under mild conditions: a direct approach to synthesize carbamates Chem. Commun. 2014, 50, 3706 - 3709
103. Batey, R. A.; Santhakumar, V.; Yoshina-Ishii, C.; Taylor, S. D. An efficient new protocol for the formation of unsymmetrical tri- and tetrasubstituted ureas Tetrahedron Lett. 1998, 39, 6267 - 6270
104. Batey, R. A.; Yoshina-Ishii, C.; Taylor, S. D.; Santhakumar, V. A new protocol for the formation of carbamates and thiocarbamates using carbamoyl imidazolium salts Tetrahedron Lett. 1999, 40, 2669 - 2672
105. Grzyb, J. A.; Batey, R. A. Carbamoylimidazolium salts as diversification reagents: an application to the synthesis of tertiary amides from carboxylic acids Tetrahedron Lett. 2003, 44, 7485 - 7488
106. Grzyb, J. A.; Shen, M.; Yoshina-Ishii, C.; Chi, W.; Brown, R. S.; Batey, R. A. Carbamoylimidazolium and thiocarbamoylimidazolium salts: novel reagents for the synthesis of ureas, thioureas, carbamates, thiocarbamates and amides Tetrahedron 2005, 61, 7153 - 7175
107. Blass, B. E. KF/Al2O3 mediated organic synthesis Tetrahedron 2002, 58, 9301 - 9320
108. Bright, Z. R.; Luyeye, C. R.; Morton, A. S.; Sedenko, M.; Landolt, R. G.; Bronzi, M. J.; Bohovic, K. M.; Gonser, M. W.; Lapainis, T. E.; Hendrickson, W. H. Competing reactions of secondary alcohols with sodium hypochlorite promoted by phase-transfer catalysis J. Org. Chem. 2005, 70, 684 - 687
109. Lebel, H.; Leogane, O. Boc-protected amines via a mild and efficient one-pot Curtius rearrangement Org. Lett. 2005, 7, 4107 - 4110
110. Lebel, H.; Leogane, O. Curtius rearrangement of aromatic carboxylic acids to access protected anilines and aromatic ureas Org. Lett. 2006, 8, 5717 - 5720
111. Leogane, O.; Lebel, H. One-pot Curtius rearrangement processes from carboxylic acids Synthesis 2009, 1935 - 1940
112. Vauthey, I.; Valot, F.; Gozzi, C.; Fache, F.; Lemaire, M. An environmentally benign access to carbamates and ureas Tetrahedron Lett. 2000, 41, 6347 - 6350
113. Pandeya, R. K.; Dagadeb, S. P.; Dongareb, M. K.; Kumara, P. Synthesis of carbamates using Yttria-Zirconia based Lewis acid catalyst Synth. Commun. 2003, 33, 4019 - 4027
114. Distaso, M.; Quaranta, E. Group 3 metal (Sc, La) triflates as catalysts for the carbomethoxylation of aliphatic amines with dimethylcarbonate under mild conditions Tetrahedron 2004, 60, 1531 - 1539
115. Zhou, H.; Shi, F.; Tian, X.; Zhang, Q.; Deng, Y. Synthesis of carbamates from aliphatic amines and dimethyl carbonate catalyzed by acid functional ionic liquids J. Mol. Catal. A: Chem. 2007, 271, 89 - 92
116. Podlech, J.; Maier, T. C. Indium in organic synthesis Synthesis 2003, 633 - 655
117. Nair, V.; Ros, S.; Jayan, C. N.; Pillai, B. S. Indium- and gallium-mediated carbon-carbon bond-forming reactions in organic synthesis Tetrahedron 2004, 60, 1959 - 1982
118. Augé, J.; Lubin-Germain, N.; Uziel, J. Recent advances in indium-promoted organic reactions Synthesis 2007, 1739 - 1764
119. Black, D. A.; Arndtsen, B. A. General approach to the coupling of organoindium reagents with imines via copper catalysis Org. Lett. 2006, 8, 1991 - 1993
120. Browne, E. J. 1,2,4-Triazoles containing nitro groups Aust. J. Chem. 1969, 22, 2251 - 2254
121. Shimizu, M.; Sodeoka, M. Convenient method for the preparation of carbamates, carbonates, and thiocarbonates Org. Lett. 2007, 9, 5231 - 5234
122. Chandrasekhar, S.; Narsihmulu, C.; Jagadeshwar, V. Ultrasound promoted 'one pot' conversion of nitrocompounds to carbamates Synlett 2002, 771 - 772
123. Porzelle, A.; Woodrow, M. D.; Tomkinson, N. C. O. Facile procedure for the synthesis of N-aryl-N-hydroxy carbamates Synlett 2009, 798 - 802
124. Liu, C. H.; Cheng, C. H. The role of alcohol in the catalytic reductive carbonylation of nitrobenzenes to carbamates in the presence of Rh(CO)4- or Ru3(CO)12 J. Organomet. Chem. 1991, 420, 119 - 123
125. Mizuno, T.; Alper, H. Reductive carbonylation of nitrobenzenes catalyzed by a new binuclear rhodium complex J. Mol. Catal. A: Chem. 1997, 121, 119 - 122
126. Wehman, P.; Kamer, P. C. J.; van Leeuwen, P. W. N. M. Reductive carbonylation of aromatic dinitro compounds with a palladium(phenanthroline)2(triflate)2 catalyst and an aromatic carboxylic acid as cocatalyst Chem. Commun. 1996, 217 - 218
127. Chuang, S. S. C.; Chen, B. J. P. The synthesis of carbamate from the reductive carbonylation of nitrobenzene over Pd-based catalysts. In Catalysis of Organic Reactions; Sowa, J. R., Jr., Ed.; Taylor & Francis: Boca Raton, FL, 2005; Chapter 52.
128. Krogul, A.; Skupińska, J.; Litwinienko, G. Catalytic activity of PdCl2 complexes with pyridines in nitrobenzene carbonylation J. Mol. Catal. A: Chem. 2011, 337, 9 - 16
129. Shivarkar, A. B.; Gupte, S. P.; Chaudhari, R. V. Carbamate synthesis via transfunctionalization of substituted ureas and carbonates J. Mol. Catal. A: Chem. 2004, 223, 85 - 92
130. Shaikh, A. A. G.; Sivaram, S. Dialkyl and diaryl carbonates by carbonate interchange reaction with dimethyl carbonate Ind. Eng. Chem. Res. 1992, 31, 1167 - 1170
131. Suciu, E. N.; Kuhlmann, B.; Knudsen, G. A.; Michaelson, R. C. Investigation of dialkyltin compounds as catalysts for the synthesis of dialkyl carbonates from alkyl carbamates J. Organomet. Chem. 1998, 556, 41 - 54
132. Han, C.; Porco, J. R. Synthesis of carbamates and ureas using Zr(IV)-catalyzed exchange processes Org. Lett. 2007, 9, 1517 - 1520
133. Padiya, K. J.; Gavade, S.; Kardile, B.; Tiwari, M.; Bajare, S.; Mane, M.; Gaware, V.; Varghese, S.; Harel, D.; Kurhade, S. Unprecedented "in water" imidazole carbonylation: paradigm shift for preparation of urea and carbamate Org. Lett. 2012, 14, 2814 - 2817
134. Kreye, O.; Wald, S.; Meiera, M. A. R. Introducing catalytic Lossen rearrangements: sustainable access to carbamates and amines Adv. Synth. Catal. 2013, 355, 81 - 86
135. Dube, P.; Nathel, N. F.; Vetelino, M.; Couturier, M.; Aboussafy, C. L.; Pichette, S.; Jorgensen, M. L.; Hardink, M. Carbonyldiimidazole-mediated Lossen rearrangement Org. Lett. 2009, 11, 5622 - 5625
136. Hamon, F.; Prié, G.; Lecornué, F.; Papot, S. Cyanuric chloride: an efficient reagent for the Lossen rearrangement Tetrahedron Lett. 2009, 50, 6800 - 6802
137. Williams, B. R.; Nazarians, A.; Gill, M. A. A review of rivastigmine: a reversible cholinesterase inhibitor Clin. Ther. 2003, 25, 1634 - 1653
138. Emre, M.; Aarsland, D.; Albanese, A.; Byrne, E. J.; Deuschl, G.; De Deyn, P. P.; Durif, F.; Kulisevsky, J.; van Laar, T.; Lees, A.; Poewe, W.; Robillard, A.; Rosa, M. M.; Wolters, E.; Quarg, P.; Tekin, S.; Lane, R. Rivastigmine for dementia associated with Parkinson's disease N. Engl. J. Med. 2004, 351, 2509 - 2518
139. Inglis, F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia Int. J. Clin. Pract., Suppl. 2002, 45 - 63
140. Devasthale, P. V.; Chen, S.; Jeon, Y.; Qu, F.; Shao, C.; Wang, W.; Zhang, H.; Cap, M.; Farrelly, D.; Golla, R.; Grover, G.; Harrity, T.; Ma, Z.; Moore, L.; Ren, J.; Seethala, R.; Cheng, L.; Sleph, P.; Sun, W.; Tieman, A.; Wetterau, J. R.; Doweyko, A.; Chandrasena, G.; Chang, S. Y.; Humphreys, W. G.; Sasseville, V. G.; Biller, S. A.; Ryono, D. E.; Selan, F.; Hariharan, N.; Cheng, P. T. Design and synthesis of N -[(4-methoxyphenoxy)carbonyl]- N -[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities J. Med. Chem. 2005, 48, 2248 - 2250
141. Bristol-Myers Squibb announces discontinuation of development of investigational oral treatment for type 2 diabetes. http://www.chemeurope.com/en/news/54972/bristol-myers-squibb-announces-discontinuation-of-development-of-investigational-oral-treatment-for-type-2-diabetes.html (accessed November 15, 2014).
142. Mousa, S. A.; DeGrado, W. F.; Mu, D. X.; Kapil, R. P.; Lucchesi, B. R.; Reilly, T. M. Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonist Circulation 1996, 93, 537 - 543
143. Xue, C. B.; Wityak, J.; Sielecki, T. M.; Pinto, D. J.; Batt, D. G.; Cain, G. A.; Sworin, M.; Rockwell, A. L.; Roderick, J. J.; Wang, S.; Orwat, M. J.; Frietze, W. E.; Bostrom, L. L.; Liu, J.; Higley, C. A.; Rankin, F. W.; Tobin, A. E.; Emmett, G.; Lalka, G. K.; Sze, J. Y.; Di Meo, S. V.; Mousa, S. A.; Thoolen, M. J.; Racanelli, A. L.; Hausner, E. A.; Reilly, T. M.; DeGrado, W. F.; Wexler, R. R.; Olson, R. E. Discovery of an orally active series of isoxazoline glycoprotein IIb/IIIa antagonists J. Med. Chem. 1997, 40, 2064 - 2084
144. Saito, A.; Yamashita, T.; Mariko, Y.; Nosaka, Y.; Tsuchiya, K.; Ando, T.; Suzuki, T.; Tsuruo, T.; Nakanishi, O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 4592 - 4597
145. Jaboin, J.; Wild, J.; Hamidi, H.; Khanna, C.; Kim, C. J.; Robey, R.; Bates, S. E.; Thiele, C. J. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors Cancer Res. 2002, 62, 6108 - 6115
146. Rosato, R. R.; Almenara, J. A.; Grant, S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1 Cancer Res. 2003, 63, 3637 - 3645
147. Lanchote, V. L.; Takayanagui, O. M.; Mateus, F. H. Enantioselective renal excretion of albendazole metabolites in patients with neurocysticercosis Chirality 2004, 16, 520 - 525
148. Luder, P. J.; Siffert, B.; Witassek, F.; Meister, F.; Bircher, J. Treatment of hydatid disease with high oral doses of mebendazole. Long-term follow-up of plasma mebendazole levels and drug interactions Eur. J. Clin. Pharmacol. 1986, 31, 443 - 448
149. Teva Pharmaceuticals product line changes: mebendazole tablets. http://www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/UCM277319.pdf (accessed September 1, 2014).
150. Jakovlev, V.; Achterrath-Tuckermann, U.; von Schlichtegroll, A.; Stroman, F.; Thiemer, K. [General pharmacologic studies on the analgesic flupirtine] Arzneimittelforschung 1985, 35, 44 - 55
151. Seaman, C. A.; Sheridan, P. H.; Engel, J.; Molliere, M.; Narang, P. K.; Nice, F. J. Flupirtine. In New Anticonvulsant Drugs; Meldrum, B. S.; Porter, R. J., Eds.; Libbey: London, 1986.
152. Seydel, J. K.; Schaper, K. J.; Coats, E. A.; Cordes, H. P.; Emig, P.; Engel, J.; Kutscher, B.; Polymeropoulos, E. E. Synthesis and quantitative structure-activity relationships of anticonvulsant 2,3,6-triaminopyridines J. Med. Chem. 1994, 37, 3016 - 3022
153. White, H. S.; Wolf, H. H.; Swinyard, E. A.; Skeen, G. A.; Sofia, R. D. A neuropharmacological evaluation of felbamate as a novel anticonvulsant Epilepsia 1992, 33, 564 - 572
154. Patsalos, P. N. Drug interactions with the newer antiepileptic drugs (AEDs)-part 1: pharmacokinetic and pharmacodynamic interactions between AEDs Clin. Pharmacokinet. 2013, 52, 927 - 966
155. Wagner, M. L.; Graves, N. M.; Marienau, K.; Holmes, G. B.; Remmel, R. P.; Leppik, I. E. Discontinuation of phenytoin and carbamazepine in patients receiving felbamate Epilepsia 1991, 32, 398 - 406
156. Reidenberg, P.; Glue, P.; Banfield, C. R.; Colucci, R. D.; Meehan, J. W.; Radwanski, E.; Mojavarian, P.; Lin, C. C.; Nezamis, J.; Guillaume, M.; Affrime, M. B. Effects of felbamate on the pharmacokinetics of phenobarbital Clin. Pharmacol. Ther. 1995, 58, 279 - 287
157. Best, B. M.; Goicoechea, M. Efavirenz-still first-line king? Expert Opin. Drug. Metab. Toxicol. 2008, 4, 965 - 972
158. Sierra-Madero, J.; Villasis-Keever, A.; Mendez, P.; Mosqueda-Gomez, J. L.; Torres-Escobar, I.; Gutierrez-Escolano, F.; Juarez-Kasusky, I.; Magana-Aquino, M.; Ramos-Santos, C.; Perez-Saleme, L.; Rangel-Frausto, S.; Antuna-Puente, B.; Soto-Ramirez, L. E.; Lima, V.; Belaunzaran-Zamudio, F.; Crabtree-Ramirez, B.; Montaner, J. Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico J. Acquired Immune Defic. Syndr. 2010, 53, 582 - 588
159. Ogburn, E. T.; Jones, D. R.; Masters, A. R.; Xu, C.; Guo, Y.; Desta, Z. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation Drug. Metab. Dispos. 2010, 38, 1218 - 1229
160. Ward, B. A.; Gorski, J. C.; Jones, D. R.; Hall, S. D.; Flockhart, D. A.; Desta, Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity J. Pharmacol. Exp. Ther. 2003, 306, 287 - 300
161. Desta, Z.; Saussele, T.; Ward, B.; Blievernicht, J.; Li, L.; Klein, K.; Flockhart, D. A.; Zanger, U. M. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro Pharmacogenomics 2007, 8, 547 - 558
162. Phipatanakul, W.; Eggleston, P. A.; Conover-Walker, M. K.; Kesavanathan, J.; Sweitzer, D.; Wood, R. A. A randomized, double-blind, placebo-controlled trial of the effect of zafirlukast on upper and lower respiratory responses to cat challenge J. Allergy Clin. Immunol. 2000, 105, 704 - 710
163. Matassa, V. G.; Maduskuie, T. P., Jr.; Shapiro, H. S.; Hesp, B.; Snyder, D. W.; Aharony, D.; Krell, R. D.; Keith, R. A. Evolution of a series of peptidoleukotriene antagonists: synthesis and structure/activity relationships of 1,3,5-substituted indoles and indazoles J. Med. Chem. 1990, 33, 1781 - 1790
164. Dekhuijzen, P. N.; Koopmans, P. P. Pharmacokinetic profile of zafirlukast Clin. Pharmacokinet. 2002, 41, 105 - 114
165. Szybalski, W.; Iyer, V. N. Crosslinking of DNA by enzymatically or chemically activated mitomycins and porfiromycins, bifunctionally "alkylating" antibiotics Fed. Proc. 1964, 23, 946 - 957
166. Hopkins, P. B.; Millard, J. T.; Woo, J.; Weidner, M. F.; Kirchner, J. J.; Sigurdsson, S. T.; Raucher, S. Sequence preferences of DNA interstrand cross-linking agents-importance of minimal DNA structural reorganization in the cross-linking reactions of mechlorethamine, cisplatin, and mitomycin-C Tetrahedron 1991, 47, 2475 - 2489
167. Alley, S. C.; Brameld, K. A.; Hopkins, P. B. DNA interstrand cross-linking by 2,5-bis(1-aziridinyl)-1,6-benzoquinone-nucleotide-sequence preferences and covalent structure of the Dg-to-Dg cross-links at 5′-D(Gn(N)C) in synthetic oligonucleotide duplexes J. Am. Chem. Soc. 1994, 116, 2734 - 2741
168. Snodgrass, R. G.; Collier, A. C.; Coon, A. E.; Pritsos, C. A. Mitomycin C inhibits ribosomal RNA: a novel cytotoxic mechanism for bioreductive drugs J. Biol. Chem. 2010, 285, 19068 - 19075
169. Verweij, J.; Pinedo, H. M. Mitomycin C: mechanism of action, usefulness and limitations Anticancer Drugs 1990, 1, 5 - 13
170. Kohl, N. E.; Emini, E. A.; Schleif, W. A.; Davis, L. J.; Heimbach, J. C.; Dixon, R. A.; Scolnick, E. M.; Sigal, I. S. Active human immunodeficiency virus protease is required for viral infectivity Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 4686 - 4690
171. Lunney, E. A.; Humblet, C. Structure-based design: from renin to HIV protease. Structure-Based Ligand Design; Gubernator, K.; Böhm, H.-J., Eds.; Wiley-VCH Verlag GmbH: New York, 1998.
172. Navia, M. A.; Fitzgerald, P. M.; McKeever, B. M.; Leu, C. T.; Heimbach, J. C.; Herber, W. K.; Sigal, I. S.; Darke, P. L.; Springer, J. P. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1 Nature 1989, 337, 615 - 620
173. Wlodawer, A.; Miller, M.; Jaskolski, M.; Sathyanarayana, B. K.; Baldwin, E.; Weber, I. T.; Selk, L. M.; Clawson, L.; Schneider, J.; Kent, S. B. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease Science 1989, 245, 616 - 621
174. Lapatto, R.; Blundell, T.; Hemmings, A.; Overington, J.; Wilderspin, A.; Wood, S.; Merson, J. R.; Whittle, P. J.; Danley, D. E.; Geoghegan, K. F.; Hawrylik, S. J.; Lee, S. E.; Scheld, K. G.; Hobart, P. M. X-ray analysis of HIV-1 proteinase at 2.7 A resolution confirms structural homology among retroviral enzymes Nature 1989, 342, 299 - 302
175. New drugs-reports of new drugs recently approved by the FDA. Ritonavir. Bioorg. Med. Chem. 1997, 5, 461 - 462.
176. Sevrioukova, I. F.; Poulos, T. L. Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 18422 - 18427
177. St Clair, M. H.; Millard, J.; Rooney, J.; Tisdale, M.; Parry, N.; Sadler, B. M.; Blum, M. R.; Painter, G. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents Antiviral Res. 1996, 29, 53 - 56
178. Ghosh, A. K.; Thompson, W. J.; McKee, S. P.; Duong, T. T.; Lyle, T. A.; Chen, J. C.; Darke, P. L.; Zugay, J. A.; Emini, E. A.; Schleif, W. A.; Huff, J. R.; Anderson, P. F. 3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors J. Med. Chem. 1993, 36, 292 - 294
179. Kim, E. E.; Baker, C. T.; Dwyer, M. D.; Murcko, M. A.; Rao, B. G.; Tung, R. D.; Navia, M. A. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme J. Am. Chem. Soc. 1995, 117, 1181 - 1182
180. Sadler, B. M.; Hanson, C. D.; Chittick, G. E.; Symonds, W. T.; Roskell, N. S. Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults Antimicrob. Agents Chemother. 1999, 43, 1686 - 1692
181. http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm125077.htm (accessed September 1, 2014).
182. Bold, G.; Fassler, A.; Capraro, H. G.; Cozens, R.; Klimkait, T.; Lazdins, J.; Mestan, J.; Poncioni, B.; Rosel, J.; Stover, D.; Tintelnot-Blomley, M.; Acemoglu, F.; Beck, W.; Boss, E.; Eschbach, M.; Hurlimann, T.; Masso, E.; Roussel, S.; Ucci-Stoll, K.; Wyss, D.; Lang, M. New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development J. Med. Chem. 1998, 41, 3387 - 3401
183. Robinson, B. S.; Riccardi, K. A.; Gong, Y. F.; Guo, Q.; Stock, D. A.; Blair, W. S.; Terry, B. J.; Deminie, C. A.; Djang, F.; Colonno, R. J.; Lin, P. F. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents Antimicrob. Agents Chemother. 2000, 44, 2093 - 2099
184. Le Tiec, C.; Barrail, A.; Goujard, C.; Taburet, A. M. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir Clin. Pharmacokinet. 2005, 44, 1035 - 1050
185. Ghosh, A. K.; Chapsal, B. D.; Weber, I. T.; Mitsuya, H. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance Acc. Chem. Res. 2008, 41, 78 - 86
186. Koh, Y.; Nakata, H.; Maeda, K.; Ogata, H.; Bilcer, G.; Devasamudram, T.; Kincaid, J. F.; Boross, P.; Wang, Y. F.; Tie, Y.; Volarath, P.; Gaddis, L.; Harrison, R. W.; Weber, I. T.; Ghosh, A. K.; Mitsuya, H. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro Antimicrob. Agents Chemother. 2003, 47, 3123 - 3129
187. De Meyer, S.; Azijn, H.; Surleraux, D.; Jochmans, D.; Tahri, A.; Pauwels, R.; Wigerinck, P.; de Bethune, M. P. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates Antimicrob. Agents Chemother. 2005, 49, 2314 - 2321
188. FDA approves new HIV treatment for patients who do not respond to existing drugs. http://www.fda.gov/newsEvents/Newsroom/PressAnnouncements/2006/ucm108676.htm (accessed September 10, 2014).
189. Rittweger, M.; Arasteh, K. Clinical pharmacokinetics of darunavir Clin. Pharmacokinet. 2007, 46, 739 - 756
190. Fujimoto, H.; Higuchi, M.; Watanabe, H.; Koh, Y.; Ghosh, A. K.; Mitsuya, H.; Tanoue, N.; Hamada, A.; Saito, H. P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines Biol. Pharm. Bull. 2009, 32, 1588 - 1593
191. Vermeir, M.; Lachau-Durand, S.; Mannens, G.; Cuyckens, F.; van Hoof, B.; Raoof, A. Absorption, metabolism, and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects Drug Metab. Dispos. 2009, 37, 809 - 820
192. Stella, V. J. Prodrugs: Challenges and Rewards. Springer:, New York, 2007.
193. Rautio, J.; Kumpulainen, H.; Heimbach, T.; Oliyai, R.; Oh, D.; Jarvinen, T.; Savolainen, J. Prodrugs: design and clinical applications Nat. Rev. Drug Discovery 2008, 7, 255 - 270
194. Mahato, R.; Tai, W.; Cheng, K. Prodrugs for improving tumor targetability and efficiency Adv. Drug. Delivery Rev. 2011, 63, 659 - 670
195. Florencio Zaragoza, D. Lead Optimization for Medicinal Chemists: Pharmacokinetic Properties of Functional Groups and Organic Compounds. 1 st ed.; Wiley-VCH: Weinheim, Germany, 2012.
196. Bundgaard, H.; Buur, A.; Lee, V. H. Timolol prodrugs: preparation and hydrolysis kinetics of N-benzoyl carbamate esters of timolol and related compounds Acta Pharm. Suec. 1988, 25, 293 - 306
197. Springer, C. J.; Dowell, R.; Burke, P. J.; Hadley, E.; Davis, D. H.; Blakey, D. C.; Melton, R. G.; Niculescu-Duvaz, I. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT) J. Med. Chem. 1995, 38, 5051 - 5065
198. Springer, C. J.; Niculescu-Duvaz, I. I. Antibody-directed enzyme prodrug therapy (ADEPT): a review Adv. Drug. Delivery Rev. 1997, 26, 151 - 172
199. Niculescu-Duvaz, I.; Springer, C. J. Introduction to the background, principles, and state of the art in suicide gene therapy Methods Mol. Med. 2004, 90, 1 - 27
200. Francis, R. J.; Sharma, S. K.; Springer, C.; Green, A. J.; Hope-Stone, L. D.; Sena, L.; Martin, J.; Adamson, K. L.; Robbins, A.; Gumbrell, L.; O'Malley, D.; Tsiompanou, E.; Shahbakhti, H.; Webley, S.; Hochhauser, D.; Hilson, A. J.; Blakey, D.; Begent, R. H. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours Br. J. Cancer 2002, 87, 600 - 607
201. Blakey, D. C.; Burke, P. J.; Davies, D. H.; Dowell, R. I.; East, S. J.; Eckersley, K. P.; Fitton, J. E.; McDaid, J.; Melton, R. G.; Niculescu-Duvaz, I. A.; Pinder, P. E.; Sharma, S. K.; Wright, A. F.; Springer, C. J. ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts Cancer Res. 1996, 56, 3287 - 3292
202. Niculescu-Duvaz, D.; Scanlon, I.; Niculescu-Duvaz, I.; Springer, C. J. A higher yielding synthesis of the clinical prodrug ZD2767P using di-protected 4-[ N, N -bis(2-hydroxyethyl)amino]phenyl chloroformate Tetrahedron Lett. 2005, 46, 6919 - 6922
203. Bencharit, S.; Morton, C. L.; Howard-Williams, E. L.; Danks, M. K.; Potter, P. M.; Redinbo, M. R. Structural insights into CPT-11 activation by mammalian carboxylesterases Nat. Struct. Biol. 2002, 9, 337 - 342
204. Sanghani, S. P.; Quinney, S. K.; Fredenburg, T. B.; Davis, W. I.; Murry, D. J.; Bosron, W. F. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4- N -(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3 Drug. Metab. Dispos. 2004, 32, 505 - 511
205. Slatter, J. G.; Su, P.; Sams, J. P.; Schaaf, L. J.; Wienkers, L. C. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions Drug Metab. Dispos. 1997, 25, 1157 - 1164
206. Svensson, L. A.; Tunek, A. The design and bioactivation of presystemically stable prodrugs Drug. Metab. Rev. 1988, 19, 165 - 194
207. Tunek, A.; Levin, E.; Svensson, L. A. Hydrolysis of 3 H -bambuterol, a carbamate prodrug of terbutaline, in blood from humans and laboratory animals in vitro Biochem. Pharmacol. 1988, 37, 3867 - 3876
208. Persson, G.; Pahlm, O.; Gnosspelius, Y. Oral Bambuterol versus Terbutaline in patients with asthma Curr. Ther. Res. Clin. E 1995, 56, 457 - 465
209. Saari, W. S.; Schwering, J. E.; Lyle, P. A.; Smith, S. J.; Engelhardt, E. L. Cyclization-activated prodrugs. Basic carbamates of 4-hydroxyanisole J. Med. Chem. 1990, 33, 97 - 101
210. Saari, W. S.; Schwering, J. E.; Lyle, P. A.; Smith, S. J.; Engelhardt, E. L. Cyclization-activated prodrugs. Basic esters of 5-bromo-2′-deoxyuridine J. Med. Chem. 1990, 33, 2590 - 2595
211. Lougerstay-Madec, R.; Florent, J. C.; Monneret, C.; Nemati, F.; Poupon, M. F. Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard Anti-Cancer Drug Des. 1998, 13, 995 - 1007
212. Zhang, Z.; Tanabe, K.; Hatta, H.; Nishimoto, S. Bioreduction activated prodrugs of camptothecin: molecular design, synthesis, activation mechanism and hypoxia selective cytotoxicity Org. Biomol. Chem. 2005, 3, 1905 - 1910
213. de Groot, F. M. H.; van Berkom, L. W. A.; Scheeren, H. W. Synthesis and biological evaluation of 2′-carbamate-linked and 2′-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin J. Med. Chem. 2000, 43, 3093 - 3102
214. de Groot, F. M. H.; Loos, W. J.; Koekkoek, R.; van Berkom, L. W. A.; Busscher, G. F.; Seelen, A. E.; Albrecht, C.; de Bruijn, P.; Scheeren, H. W. Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug release J. Org. Chem. 2001, 66, 8815 - 8830
215. Cundy, K. C.; Annamalai, T.; Bu, L.; De Vera, J.; Estrela, J.; Luo, W.; Shirsat, P.; Torneros, A.; Yao, F.; Zou, J.; Barrett, R. W.; Gallop, M. A. XP13512 [(±)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys J. Pharmacol. Exp. Ther. 2004, 311, 324 - 333
216. Cundy, K. C.; Branch, R.; Chernov-Rogan, T.; Dias, T.; Estrada, T.; Hold, K.; Koller, K.; Liu, X.; Mann, A.; Panuwat, M.; Raillard, S. P.; Upadhyay, S.; Wu, Q. Q.; Xiang, J. N.; Yan, H.; Zerangue, N.; Zhou, C. X.; Barrett, R. W.; Gallop, M. A. XP13512 [(±)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters J. Pharmacol. Exp. Ther. 2004, 311, 315 - 323
217. Cundy, K. C.; Sastry, S.; Luo, W.; Zou, J.; Moors, T. L.; Canafax, D. M. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin J. Clin. Pharmacol. 2008, 48, 1378 - 1388
218. HORIZANT: NDA 022399-FDA approved labeling text. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/022399s006,s007lbl.pdf (accessed September 1, 2014).
219. Quinney, S. K.; Sanghani, S. P.; Davis, W. I.; Hurley, T. D.; Sun, Z.; Murry, D. J.; Bosron, W. F. Hydrolysis of capecitabine to 5′-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide J. Pharmacol. Exp. Ther. 2005, 313, 1011 - 1016
220. Miwa, M.; Ura, M.; Nishida, M.; Sawada, N.; Ishikawa, T.; Mori, K.; Shimma, N.; Umeda, I.; Ishitsuka, H. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue Eur. J. Cancer. 1998, 34, 1274 - 1281
221. Venturini, M. Rational development of capecitabine Eur. J. Cancer 2002, 38, 3 - 9
222. Walko, C. M.; Lindley, C. Capecitabine: a review Clin. Ther. 2005, 27, 23 - 44
223. Muller, T. H.; Weisenberger, H.; Brickl, R.; Narjes, H.; Himmelsbach, F.; Krause, J. Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men Circulation 1997, 96, 1130 - 1138
224. Ghosh, A. K.; Ramu Sridhar, P.; Kumaragurubaran, N.; Koh, Y.; Weber, I. T.; Mitsuya, H. Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of hiv protease inhibitors that combat drug resistance ChemMedChem 2006, 1, 939 - 950
225. Ghosh, A. K.; Anderson, D. D.; Weber, I. T.; Mitsuya, H. Enhancing protein backbone binding-a fruitful concept for combating drug-resistant HIV Angew. Chem., Int. Ed. 2012, 51, 1778 - 1802
226. Hong, L.; Zhang, X. C.; Hartsuck, J. A.; Tang, J. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance Protein Sci. 2000, 9, 1898 - 1904
227. Ghosh, A. K.; Thompson, W. J.; Holloway, M. K.; McKee, S. P.; Duong, T. T.; Lee, H. Y.; Munson, P. M.; Smith, A. M.; Wai, J. M.; Darke, P. L.; Zugay, J. A.; Emini, E. A.; Schleif, W. A.; Huff, J. R.; Anderson, P. F. Potent HIV protease inhibitors: the development of tetrahydrofuranylglycines as novel P2-ligands and pyrazine amides as P3-ligands J. Med. Chem. 1993, 36, 2300 - 2310
228. Ghosh, A. K.; Chapsal, B. D. Anti-HIV protease inhibitor Darunavir. In Introduction to Biopharmaceuticals and Small Molecule Drug Research and Development: Theory and Case Studies; Ganellin, R.; Jefferis, R.; Roberts, S., Eds.; Elsevier: Waltham, MA, 2013; pp 355 - 384.
229. Vazquez, M. L.; Bryant, M. L.; Clare, M.; DeCrescenzo, G. A.; Doherty, E. M.; Freskos, J. N.; Getman, D. P.; Houseman, K. A.; Julien, J. A.; Kocan, G. P.; Mueller, R. A.; Shieh, H.-S.; Stallings, W. C.; Stegeman, R. A.; Talley, J. J. Inhibitors of HIV-1 protease containing the novel and potent (R)-(hydroxyethyl)sulfonamide isostere J. Med. Chem. 1995, 38, 581 - 584
230. Tung, R. D.; Livingston, D. J.; Rao, B. G.; Kim, E. E.; Baker, C. T.; Boger, J. S.; Chambers, S. P.; Deininger, D. D.; Dwyer, M.; Elsayed, L.; Fulghum, J.; Li, B.; Murcko, M. A.; Navia, M. A.; Novak, P.; Pazhanisamy, S.; Stuver, C.; Thomson, J. A., Design and synthesis of Amprenavir, a novel HIV protease inhibitor. In Protease Inihitors in AIDS Therapy; Ogden, R. C.; Flexner, C. W., Eds.; Marcel Dekker Inc.: New York, 2001; pp 101 - 137.
231. Ghosh, A. K.; Lee, H. Y.; Thompson, W. J.; Culberson, C.; Holloway, M. K.; McKee, S. P.; Munson, P. M.; Duong, T. T.; Smith, A. M.; Darke, P. L.; Zugay, J. A.; Emini, E. A.; Schleif, W. A.; Huff, J. R.; Anderson, P. F. The development of cyclic sulfolanes as novel and high-affinity P2 ligands for HIV-1 protease inhibitors J. Med. Chem. 1994, 37, 1177 - 1188
232. Ghosh, A. K.; Kincaid, J. F.; Walters, D. E.; Chen, Y.; Chaudhuri, N. C.; Thompson, W. J.; Culberson, C.; Fitzgerald, P. M.; Lee, H. Y.; McKee, S. P.; Munson, P. M.; Duong, T. T.; Darke, P. L.; Zugay, J. A.; Schleif, W. A.; Axel, M. G.; Lin, J.; Huff, J. R. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation J. Med. Chem. 1996, 39, 3278 - 3290
233. Ghosh, A. K.; Shin, D.; Swanson, L.; Krishnan, K.; Cho, H.; Hussain, K. A.; Walters, D. E.; Holland, L.; Buthod, J. Structure-based design of non-peptide HIV protease inhibitors Farmaco 2001, 56, 29 - 32
234. Ghosh, A. K.; Kincaid, J. F.; Cho, W.; Walters, D. E.; Krishnan, K.; Hussain, K. A.; Koo, Y.; Cho, H.; Rudall, C.; Holland, L.; Buthod, J. Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere Bioorg. Med. Chem. Lett. 1998, 8, 687 - 690
235. Tie, Y.; Boross, P. I.; Wang, Y. F.; Gaddis, L.; Hussain, A. K.; Leshchenko, S.; Ghosh, A. K.; Louis, J. M.; Harrison, R. W.; Weber, I. T. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains J. Mol. Biol. 2004, 338, 341 - 352
236. Kovalevsky, A. Y.; Liu, F.; Leshchenko, S.; Ghosh, A. K.; Louis, J. M.; Harrison, R. W.; Weber, I. T. Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114 J. Mol. Biol. 2006, 363, 161 - 173
237. Yoshimura, K.; Kato, R.; Kavlick, M. F.; Nguyen, A.; Maroun, V.; Maeda, K.; Hussain, K. A.; Ghosh, A. K.; Gulnik, S. V.; Erickson, J. W.; Mitsuya, H. A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site J. Virol. 2002, 76, 1349 - 1358
238. Koh, Y.; Matsumi, S.; Das, D.; Amano, M.; Davis, D. A.; Li, J.; Leschenko, S.; Baldridge, A.; Shioda, T.; Yarchoan, R.; Ghosh, A. K.; Mitsuya, H. Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization J. Biol. Chem. 2007, 282, 28709 - 28720
239. Surleraux, D. L.; de Kock, H. A.; Verschueren, W. G.; Pille, G. M.; Maes, L. J.; Peeters, A.; Vendeville, S.; De Meyer, S.; Azijn, H.; Pauwels, R.; de Bethune, M. P.; King, N. M.; Prabu-Jeyabalan, M.; Schiffer, C. A.; Wigerinck, P. B. Design of HIV-1 protease inhibitors active on multidrug-resistant virus J. Med. Chem. 2005, 48, 1965 - 1973
240. Ghosh, A. K.; Dawson, Z. L.; Mitsuya, H. Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV Bioorg. Med. Chem. 2007, 15, 7576 - 7580
241. Ghosh, A. K.; Chapsal, B. D.; Mitsuya, H., Darunavir, a new PI with dual mechanism: from a novel drug design concept to new hope against drug-resistant HIV. In Aspartic Acid Proteases as Therapeutic Targets; Ghosh, A. K., Ed.; Wiley-VCH: Weinheim, Germany, 2010; Vol. 45, pp 205 - 243.
242. Ghosh, A. K.; Leshchenko, S.; Noetzel, M. Stereoselective photochemical 1,3-dioxolane addition to 5-alkoxymethyl-2(5 H)-furanone: synthesis of bis-tetrahydrofuranyl ligand for HIV protease inhibitor UIC-94017 (TMC-114) J. Org. Chem. 2004, 69, 7822 - 7829
243. Ghosh, A. K.; Chen, Y. Synthesis and optical resolution of high affinity P2-ligands for HIV-1 protease inhibitors Tetrahedron Lett. 1995, 36, 505 - 508
244. Amano, M.; Koh, Y.; Das, D.; Li, J.; Leschenko, S.; Wang, Y. F.; Boross, P. I.; Weber, I. T.; Ghosh, A. K.; Mitsuya, H. A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro Antimicrob. Agents Chemother. 2007, 51, 2143 - 2155
245. Miller, J. F.; Andrews, C. W.; Brieger, M.; Furfine, E. S.; Hale, M. R.; Hanlon, M. H.; Hazen, R. J.; Kaldor, I.; McLean, E. W.; Reynolds, D.; Sammond, D. M.; Spaltenstein, A.; Tung, R.; Turner, E. M.; Xu, R. X.; Sherrill, R. G. Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385 Bioorg. Med. Chem. Lett. 2006, 16, 1788 - 1794
246. Cihlar, T.; He, G. X.; Liu, X.; Chen, J. M.; Hatada, M.; Swaminathan, S.; McDermott, M. J.; Yang, Z. Y.; Mulato, A. S.; Chen, X.; Leavitt, S. A.; Stray, K. M.; Lee, W. A. Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring J. Mol. Biol. 2006, 363, 635 - 647
247. Dierynck, I.; Van Marck, H.; Van Ginderen, M.; Jonckers, T. H.; Nalam, M. N.; Schiffer, C. A.; Raoof, A.; Kraus, G.; Picchio, G. TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors Antimicrob. Agents Chemother. 2011, 55, 5723 - 5731
248. Ghosh, A. K.; Sridhar, P. R.; Leshchenko, S.; Hussain, A. K.; Li, J.; Kovalevsky, A. Y.; Walters, D. E.; Wedekind, J. E.; Grum-Tokars, V.; Das, D.; Koh, Y.; Maeda, K.; Gatanaga, H.; Weber, I. T.; Mitsuya, H. Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance J. Med. Chem. 2006, 49, 5252 - 5261
249. Ghosh, A. K.; Gemma, S.; Baldridge, A.; Wang, Y. F.; Kovalevsky, A. Y.; Koh, Y.; Weber, I. T.; Mitsuya, H. Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies J. Med. Chem. 2008, 51, 6021 - 6033
250. Ghosh, A. K.; Chapsal, B. D.; Baldridge, A.; Steffey, M. P.; Walters, D. E.; Koh, Y.; Amano, M.; Mitsuya, H. Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation J. Med. Chem. 2011, 54, 622 - 634
251. Ghosh, A. K.; Xu, C. X.; Rao, K. V.; Baldridge, A.; Agniswamy, J.; Wang, Y. F.; Weber, I. T.; Aoki, M.; Miguel, S. G.; Amano, M.; Mitsuya, H. Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors ChemMedChem 2010, 5, 1850 - 1854
252. Salcedo Gomez, P. M.; Amano, M.; Yashchuk, S.; Mizuno, A.; Das, D.; Ghosh, A. K.; Mitsuya, H. GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration Antimicrob. Agents Chemother. 2013, 57, 6110 - 6121
253. Ghosh, A. K.; Osswald, H. L. BACE1 (beta-secretase) inhibitors for the treatment of Alzheimer's disease Chem. Soc. Rev. 2014, 7, 6765 - 6813
254. Tang, J.; Hong, L.; Ghosh, A. K. The discovery of β-secretase and development toward a clinical inhibitor for AD: an exciting academic collaboration. In Aspartic Acid Proteases as Therapeutic Targets; Ghosh, A. K., Ed.; Wiley-VCH: Weinheim, Germany, 2010; Vol. 45, pp 413 - 440.
255. Ghosh, A. K.; Shin, D. W.; Koelsch, G.; Lin, X.; Ermolieff, J.; Tang, J. Design of potent inhibitors for human brain memapsin 2 (β-secretase) J. Am. Chem. Soc. 2000, 122, 3522 - 3523
256. Hong, L.; Koelsch, G.; Lin, X.; Wu, S.; Terzyan, S.; Ghosh, A. K.; Zhang, X. C.; Tang, J. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor Science 2000, 290, 150 - 153
257. Ghosh, A. K.; Devasamudram, T.; Hong, L.; DeZutter, C.; Xu, X.; Weerasena, V.; Koelsch, G.; Bilcer, G.; Tang, J. Structure-based design of cycloamide-urethane-derived novel inhibitors of human brain memapsin 2 (beta-secretase) Bioorg. Med. Chem. Lett. 2005, 15, 15 - 20
258. Diment, S.; Leech, M. S.; Stahl, P. D. Cathepsin D is membrane-associated in macrophage endosomes J. Biol. Chem. 1988, 263, 6901 - 6907
259. Ghosh, A. K.; Kumaragurubaran, N.; Hong, L.; Lei, H.; Hussain, K. A.; Liu, C. F.; Devasamudram, T.; Weerasena, V.; Turner, R.; Koelsch, G.; Bilcer, G.; Tang, J. Design, synthesis and X-ray structure of protein-ligand complexes: important insight into selectivity of memapsin 2 (beta-secretase) inhibitors J. Am. Chem. Soc. 2006, 128, 5310 - 5311
260. Freskos, J. N.; Fobian, Y. M.; Benson, T. E.; Bienkowski, M. J.; Brown, D. L.; Emmons, T. L.; Heintz, R.; Laborde, A.; McDonald, J. J.; Mischke, B. V.; Molyneaux, J. M.; Moon, J. B.; Mullins, P. B.; Bryan Prince, D.; Paddock, D. J.; Tomasselli, A. G.; Winterrowd, G. Design of potent inhibitors of human beta-secretase. Part 1 Bioorg. Med. Chem. Lett. 2007, 17, 73 - 77
261. Freskos, J. N.; Fobian, Y. M.; Benson, T. E.; Moon, J. B.; Bienkowski, M. J.; Brown, D. L.; Emmons, T. L.; Heintz, R.; Laborde, A.; McDonald, J. J.; Mischke, B. V.; Molyneaux, J. M.; Mullins, P. B.; Bryan Prince, D.; Paddock, D. J.; Tomasselli, A. G.; Winterrowd, G. Design of potent inhibitors of human beta-secretase. Part 2 Bioorg. Med. Chem. Lett. 2007, 17, 78 - 81
262. Wong, G. T.; Manfra, D.; Poulet, F. M.; Zhang, Q.; Josien, H.; Bara, T.; Engstrom, L.; Pinzon-Ortiz, M.; Fine, J. S.; Lee, H. J.; Zhang, L.; Higgins, G. A.; Parker, E. M. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation J. Biol. Chem. 2004, 279, 12876 - 12882
263. Lanz, T. A.; Hosley, J. D.; Adams, W. J.; Merchant, K. M. Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N 2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]- N 1-[(7 S)-5-methyl-6-oxo-6,7-dihydro-5 H -dibenzo[b,d]azepin-7-yl]- l -alaninamide (LY-411575) J. Pharmacol. Exp. Ther. 2004, 309, 49 - 55
264. Best, J. D.; Jay, M. T.; Otu, F.; Ma, J.; Nadin, A.; Ellis, S.; Lewis, H. D.; Pattison, C.; Reilly, M.; Harrison, T.; Shearman, M. S.; Williamson, T. L.; Atack, J. R. Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [ N 2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]- N 1-[(7 S)-5-methyl-6-oxo-6,7-dihydro-5 H -dibenzo[b,d]azepin-7-yl]- l -alaninamide] J. Pharmacol. Exp. Ther. 2005, 313, 902 - 908
265. Peters, J. U.; Galley, G.; Jacobsen, H.; Czech, C.; David-Pierson, P.; Kitas, E. A.; Ozmen, L. Novel orally active, dibenzazepinone-based gamma-secretase inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 5918 - 5923
266. Guo, T.; Gu, H.; Hobbs, D. W.; Rokosz, L. L.; Stauffer, T. M.; Jacob, B.; Clader, J. W. Design, synthesis, and evaluation of tetrahydroquinoline and pyrrolidine sulfonamide carbamates as gamma-secretase inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 3010 - 3013
267. McBriar, M. D.; Clader, J. W.; Chu, I.; Del Vecchio, R. A.; Favreau, L.; Greenlee, W. J.; Hyde, L. A.; Nomeir, A. A.; Parker, E. M.; Pissarnitski, D. A.; Song, L.; Zhang, L.; Zhao, Z. Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 215 - 219
268. Pissarnitski, D. A.; Asberom, T.; Bara, T. A.; Buevich, A. V.; Clader, J. W.; Greenlee, W. J.; Guzik, H. S.; Josien, H. B.; Li, W.; McEwan, M.; McKittrick, B. A.; Nechuta, T. L.; Parker, E. M.; Sinning, L.; Smith, E. M.; Song, L.; Vaccaro, H. A.; Voigt, J. H.; Zhang, L.; Zhang, Q.; Zhao, Z. 2,6-Disubstituted N -arylsulfonyl piperidines as gamma-secretase inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 57 - 62
269. Bergstrom, C. P.; Sloan, C. P.; Wang, H. H.; Parker, M. F.; Smith, D. W.; Zheng, M.; Hansel, S. B.; Polson, C. T.; Barber, L. E.; Bursuker, I.; Guss, V. L.; Corsa, J. A.; Barten, D. M.; Felsenstein, K. M.; Roberts, S. B. Nitrogen-appended N -alkylsulfonamides as inhibitors of gamma-secretase Bioorg. Med. Chem. Lett. 2008, 18, 175 - 178
270. Bergstrom, C. P.; Sloan, C. P.; Lau, W. Y.; Smith, D. W.; Zheng, M.; Hansel, S. B.; Polson, C. T.; Corsa, J. A.; Barten, D. M.; Felsenstein, K. M.; Roberts, S. B. Carbamate-appended N -alkylsulfonamides as inhibitors of gamma-secretase Bioorg. Med. Chem. Lett. 2008, 18, 464 - 468
271. Heutinck, K. M.; ten Berge, I. J.; Hack, C. E.; Hamann, J.; Rowshani, A. T. Serine proteases of the human immune system in health and disease Mol. Immunol. 2010, 47, 1943 - 1955
272. Lopez-Otin, C.; Bond, J. S. Proteases: multifunctional enzymes in life and disease J. Biol. Chem. 2008, 283, 30433 - 30437
273. Powers, J. C.; Asgian, J. L.; Ekici, O. D.; James, K. E. Irreversible inhibitors of serine, cysteine, and threonine proteases Chem. Rev. 2002, 102, 4639 - 4750
274. Walker, B.; Lynas, J. F. Strategies for the inhibition of serine proteases Cell. Mol. Life Sci. 2001, 58, 596 - 624
275. Leung, D.; Abbenante, G.; Fairlie, D. P. Protease inhibitors: current status and future prospects J. Med. Chem. 2000, 43, 305 - 341
276. Perona, J. J.; Craik, C. S. Structural basis of substrate specificity in the serine proteases Protein Sci. 1995, 4, 337 - 360
277. Oleksyszyn, J.; Boduszek, B.; Kam, C. M.; Powers, J. C. Novel amidine-containing peptidyl phosphonates as irreversible inhibitors for blood coagulation and related serine proteases J. Med. Chem. 1994, 37, 226 - 231
278. Abuelyaman, A. S.; Jackson, D. S.; Hudig, D.; Woodard, S. L.; Powers, J. C. Synthesis and kinetic studies of diphenyl 1-(N-peptidylamino)alkanephosphonate esters and their biotinylated derivatives as inhibitors of serine proteases and probes for lymphocyte granzymes Arch. Biochem. Biophys. 1997, 344, 271 - 280
279. Stone, S. R. Thrombin inhibitors: a new generation of antithrombotics Trends Cardiovasc. Med. 1995, 5, 134 - 140
280. Luchtman-Jones, L.; Broze, G. J., Jr. The current status of coagulation Ann. Med. 1995, 27, 47 - 52
281. Lim, M. S.; Johnston, E. R.; Kettner, C. A. The solution conformation of (D)Phe-Pro-containing peptides: implications on the activity of Ac-(D)Phe-Pro-boroArg-OH, a potent thrombin inhibitor J. Med. Chem. 1993, 36, 1831 - 1838
282. Cacciola, J.; Fevig, J. M.; Alexander, R. S.; Brittelli, D. R.; Kettner, C. A.; Knabb, R. M.; Weber, P. C. Synthesis of conformationally-restricted boropeptide thrombin inhibitors Bioorg. Med. Chem. Lett. 1996, 6, 301 - 306
283. Imperiali, B.; Abeles, R. H. Inhibition of serine proteases by peptidyl fluoromethyl ketones Biochemistry 1986, 25, 3760 - 3767
284. Veale, C. A.; Bernstein, P. R.; Bryant, C.; Ceccarelli, C.; Damewood, J. R., Jr.; Earley, R.; Feeney, S. W.; Gomes, B.; Kosmider, B. J.; Steelman, G. B.; Thomas, R. M.; Vacek, E. P.; Williams, J. C.; Wolanin, D. J.; Woolson, S. Nonpeptidic inhibitors of human leukocyte elastase. 5. Design, synthesis, and X-ray crystallography of a series of orally active 5-aminopyrimidin-6-one-containing trifluoromethyl ketones J. Med. Chem. 1995, 38, 98 - 108
285. Bernstein, P. R.; Gomes, B. C.; Kosmider, B. J.; Vacek, E. P.; Williams, J. C. Nonpeptidic inhibitors of human leukocyte elastase. 6. Design of a potent, intratracheally active, pyridone-based trifluoromethyl ketone J. Med. Chem. 1995, 38, 212 - 215
286. Edwards, P. D.; Andisik, D. W.; Bryant, C. A.; Ewing, B.; Gomes, B.; Lewis, J. J.; Rakiewicz, D.; Steelman, G.; Strimpler, A.; Trainor, D. A.; Tuthill, P. A.; Mauger, R. C.; Veale, C. A.; Wildonger, R. A.; Williams, J. C.; Wolanin, D. J.; Zottola, M. Discovery and biological activity of orally active peptidyl trifluoromethyl ketone inhibitors of human neutrophil elastase J. Med. Chem. 1997, 40, 1876 - 1885
287. Veale, C. A.; Bernstein, P. R.; Bohnert, C. M.; Brown, F. J.; Bryant, C.; Damewood, J. R., Jr.; Earley, R.; Feeney, S. W.; Edwards, P. D.; Gomes, B.; Hulsizer, J. M.; Kosmider, B. J.; Krell, R. D.; Moore, G.; Salcedo, T. W.; Shaw, A.; Silberstein, D. S.; Steelman, G. B.; Stein, M.; Strimpler, A.; Thomas, R. M.; Vacek, E. P.; Williams, J. C.; Wolanin, D. J.; Woolson, S. Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase J. Med. Chem. 1997, 40, 3173 - 3181
288. Zoulim, F.; Chevallier, M.; Maynard, M.; Trepo, C. Clinical consequences of hepatitis C virus infection Rev. Med. Virol. 2003, 13, 57 - 68
289. Njoroge, F. G.; Chen, K. X.; Shih, N. Y.; Piwinski, J. J. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection Acc. Chem. Res. 2008, 41, 50 - 59
290. Thomson, J. A.; Perni, R. B. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic Curr. Opin. Drug Discovery Dev. 2006, 9, 606 - 617
291. Lamarre, D.; Anderson, P. C.; Bailey, M.; Beaulieu, P.; Bolger, G.; Bonneau, P.; Bos, M.; Cameron, D. R.; Cartier, M.; Cordingley, M. G.; Faucher, A. M.; Goudreau, N.; Kawai, S. H.; Kukolj, G.; Lagace, L.; LaPlante, S. R.; Narjes, H.; Poupart, M. A.; Rancourt, J.; Sentjens, R. E.; St George, R.; Simoneau, B.; Steinmann, G.; Thibeault, D.; Tsantrizos, Y. S.; Weldon, S. M.; Yong, C. L.; Llinas-Brunet, M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus Nature 2003, 426, 186 - 189
292. Venkatraman, S.; Bogen, S. L.; Arasappan, A.; Bennett, F.; Chen, K.; Jao, E.; Liu, Y. T.; Lovey, R.; Hendrata, S.; Huang, Y.; Pan, W.; Parekh, T.; Pinto, P.; Popov, V.; Pike, R.; Ruan, S.; Santhanam, B.; Vibulbhan, B.; Wu, W.; Yang, W.; Kong, J.; Liang, X.; Wong, J.; Liu, R.; Butkiewicz, N.; Chase, R.; Hart, A.; Agrawal, S.; Ingravallo, P.; Pichardo, J.; Kong, R.; Baroudy, B.; Malcolm, B.; Guo, Z.; Prongay, A.; Madison, V.; Broske, L.; Cui, X.; Cheng, K. C.; Hsieh, Y.; Brisson, J. M.; Prelusky, D.; Korfmacher, W.; White, R.; Bogdanowich-Knipp, S.; Pavlovsky, A.; Bradley, P.; Saksena, A. K.; Ganguly, A.; Piwinski, J.; Girijavallabhan, V.; Njoroge, F. G. Discovery of (1 R,5 S)- N -[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection J. Med. Chem. 2006, 49, 6074 - 6086
293. Malcolm, B. A.; Liu, R.; Lahser, F.; Agrawal, S.; Belanger, B.; Butkiewicz, N.; Chase, R.; Gheyas, F.; Hart, A.; Hesk, D.; Ingravallo, P.; Jiang, C.; Kong, R.; Lu, J.; Pichardo, J.; Prongay, A.; Skelton, A.; Tong, X.; Venkatraman, S.; Xia, E.; Girijavallabhan, V.; Njoroge, F. G. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells Antimicrob. Agents Chemother. 2006, 50, 1013 - 1020
294. Arasappan, A.; Njoroge, F. G.; Chan, T. Y.; Bennett, F.; Bogen, S. L.; Chen, K.; Gu, H.; Hong, L.; Jao, E.; Liu, Y. T.; Lovey, R. G.; Parekh, T.; Pike, R. E.; Pinto, P.; Santhanam, B.; Venkatraman, S.; Vaccaro, H.; Wang, H.; Yang, X.; Zhu, Z.; McKittrick, B.; Saksena, A. K.; Girijavallabhan, V.; Pichardo, J.; Butkiewicz, N.; Ingram, R.; Malcolm, B.; Prongay, A.; Yao, N.; Marten, B.; Madison, V.; Kemp, S.; Levy, O.; Lim-Wilby, M.; Tamura, S.; Ganguly, A. K. Hepatitis C virus NS3-4A serine protease inhibitors: SAR of P′2 moiety with improved potency Bioorg. Med. Chem. Lett. 2005, 15, 4180 - 4184
295. Bogen, S. L.; Ruan, S.; Liu, R.; Agrawal, S.; Pichardo, J.; Prongay, A.; Baroudy, B.; Saksena, A. K.; Girijavallabhan, V.; Njoroge, F. G. Depeptidization efforts on P3-P2′ alpha-ketoamide inhibitors of HCV NS3-4A serine protease: effect on HCV replicon activity Bioorg. Med. Chem. Lett. 2006, 16, 1621 - 1627
296. Bogen, S. L.; Arasappan, A.; Bennett, F.; Chen, K.; Jao, E.; Liu, Y. T.; Lovey, R. G.; Venkatraman, S.; Pan, W.; Parekh, T.; Pike, R. E.; Ruan, S.; Liu, R.; Baroudy, B.; Agrawal, S.; Chase, R.; Ingravallo, P.; Pichardo, J.; Prongay, A.; Brisson, J. M.; Hsieh, T. Y.; Cheng, K. C.; Kemp, S. J.; Levy, O. E.; Lim-Wilby, M.; Tamura, S. Y.; Saksena, A. K.; Girijavallabhan, V.; Njoroge, F. G. Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication J. Med. Chem. 2006, 49, 2750 - 2757
297. Venkatraman, S. Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections Trends Pharmacol. Sci. 2012, 33, 289 - 294
298. Boloor, A.; Hanway, D.; Joshi, M.; Winn, D. T.; Mendez, G.; Walls, M.; Wei, P.; Qian, F.; Zhang, X.; Zhang, Y.; Hepperle, M. E.; Li, X.; Campbell, D. A.; Betancort, J. M. Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 5708 - 5711
299. Li, X.; Zhang, Y. K.; Liu, Y.; Ding, C. Z.; Zhou, Y.; Li, Q.; Plattner, J. J.; Baker, S. J.; Zhang, S.; Kazmierski, W. M.; Wright, L. L.; Smith, G. K.; Grimes, R. M.; Crosby, R. M.; Creech, K. L.; Carballo, L. H.; Slater, M. J.; Jarvest, R. L.; Thommes, P.; Hubbard, J. A.; Convery, M. A.; Nassau, P. M.; McDowell, W.; Skarzynski, T. J.; Qian, X.; Fan, D.; Liao, L.; Ni, Z. J.; Pennicott, L. E.; Zou, W.; Wright, J. Novel macrocyclic HCV NS3 protease inhibitors derived from alpha-amino cyclic boronates Bioorg. Med. Chem. Lett. 2010, 20, 5695 - 5700
300. Hu, L. Y.; Abeles, R. H. Inhibition of cathepsin B and papain by peptidyl alpha-keto esters, alpha-keto amides, alpha-diketones, and alpha-keto acids Arch. Biochem. Biophys. 1990, 281, 271 - 274
301. Chen, K. X.; Njoroge, F. G.; Pichardo, J.; Prongay, A.; Butkiewicz, N.; Yao, N.; Madison, V.; Girijavallabhan, V. Design, synthesis, and biological activity of m-tyrosine-based 16- and 17-membered macrocyclic inhibitors of hepatitis C virus NS3 serine protease J. Med. Chem. 2005, 48, 6229 - 6235
302. Liu, R.; Abid, K.; Pichardo, J.; Pazienza, V.; Ingravallo, P.; Kong, R.; Agrawal, S.; Bogen, S.; Saksena, A.; Cheng, K. C.; Prongay, A.; Njoroge, F. G.; Baroudy, B. M.; Negro, F. In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease J. Antimicrob. Chemother. 2007, 59, 51 - 58
303. Venkatraman, S.; Velazquez, F.; Wu, W.; Blackman, M.; Chen, K. X.; Bogen, S.; Nair, L.; Tong, X.; Chase, R.; Hart, A.; Agrawal, S.; Pichardo, J.; Prongay, A.; Cheng, K. C.; Girijavallabhan, V.; Piwinski, J.; Shih, N. Y.; Njoroge, F. G. Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease J. Med. Chem. 2009, 52, 336 - 346
304. Edwards, P. D.; Bernstein, P. R. Synthetic inhibitors of elastase Med. Res. Rev. 1994, 14, 127 - 194
305. Gemma, S.; Brogi, S.; Novellino, E.; Campiani, G.; Maga, G.; Brindisi, M.; Butini, S. HCV-targeted antivirals: current status and future challenges Curr. Pharm. Des. 2014, 20, 3445 - 3464
306. Belda, O.; Targett-Adams, P. Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein Virus Res. 2012, 170, 1 - 14
307. Gao, M.; Nettles, R. E.; Belema, M.; Snyder, L. B.; Nguyen, V. N.; Fridell, R. A.; Serrano-Wu, M. H.; Langley, D. R.; Sun, J. H.; O'Boyle, D. R., II; Lemm, J. A.; Wang, C.; Knipe, J. O.; Chien, C.; Colonno, R. J.; Grasela, D. M.; Meanwell, N. A.; Hamann, L. G. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 2010, 465, 96 - 100
308. Guedj, J.; Dahari, H.; Rong, L.; Sansone, N. D.; Nettles, R. E.; Cotler, S. J.; Layden, T. J.; Uprichard, S. L.; Perelson, A. S. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 3991 - 3996
309. Lawitz, E. J.; Gruener, D.; Hill, J. M.; Marbury, T.; Moorehead, L.; Mathias, A.; Cheng, G.; Link, J. O.; Wong, K. A.; Mo, H.; McHutchison, J. G.; Brainard, D. M. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C J. Hepatol. 2012, 57, 24 - 31
310. Afdhal, N.; Zeuzem, S.; Kwo, P.; Chojkier, M.; Gitlin, N.; Puoti, M.; Romero-Gomez, M.; Zarski, J. P.; Agarwal, K.; Buggisch, P.; Foster, G. R.; Brau, N.; Buti, M.; Jacobson, I. M.; Subramanian, G. M.; Ding, X.; Mo, H.; Yang, J. C.; Pang, P. S.; Symonds, W. T.; McHutchison, J. G.; Muir, A. J.; Mangia, A.; Marcellin, P. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N. Engl. J. Med. 2014, 370, 1889 - 1898
311. FDA approves first combination pill to treat hepatitis C. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418365.htm (accessed November 15, 2014).
312. Barrett, A. J.; Rawlings, N. D. Evolutionary lines of cysteine peptidases Biol. Chem. 2001, 382, 727 - 733
313. Leung-Toung, R.; Zhao, Y.; Li, W.; Tam, T. F.; Karimian, K.; Spino, M. Thiol proteases: inhibitors and potential therapeutic targets Curr. Med. Chem. 2006, 13, 547 - 581
314. Buhling, F.; Fengler, A.; Brandt, W.; Welte, T.; Ansorge, S.; Nagler, D. K. Review: novel cysteine proteases of the papain family Adv. Exp. Med. Biol. 2000, 477, 241 - 254
315. Shaw, E. Cysteinyl proteinases and their selective inactivation Adv. Enzymol. Relat. Areas Mol. Biol. 1990, 63, 271 - 347
316. Santos, M. M.; Moreira, R. Michael acceptors as cysteine protease inhibitors Mini-Rev. Med. Chem. 2007, 7, 1040 - 1050
317. Vicik, R.; Busemann, M.; Baumann, K.; Schirmeister, T. Inhibitors of cysteine proteases Curr. Top. Med. Chem. 2006, 6, 331 - 353
318. Nicoll-Griffith, D. A. Use of cysteine-reactive small molecules in drug discovery for trypanosomal disease Expert Opin. Drug. Discovery 2012, 7, 353 - 366
319. Drosten, C.; Gunther, S.; Preiser, W.; van der Werf, S.; Brodt, H. R.; Becker, S.; Rabenau, H.; Panning, M.; Kolesnikova, L.; Fouchier, R. A.; Berger, A.; Burguiere, A. M.; Cinatl, J.; Eickmann, M.; Escriou, N.; Grywna, K.; Kramme, S.; Manuguerra, J. C.; Muller, S.; Rickerts, V.; Sturmer, M.; Vieth, S.; Klenk, H. D.; Osterhaus, A. D.; Schmitz, H.; Doerr, H. W. Identification of a novel coronavirus in patients with severe acute respiratory syndrome N. Engl. J. Med. 2003, 348, 1967 - 1976
320. Ksiazek, T. G.; Erdman, D.; Goldsmith, C. S.; Zaki, S. R.; Peret, T.; Emery, S.; Tong, S.; Urbani, C.; Comer, J. A.; Lim, W.; Rollin, P. E.; Dowell, S. F.; Ling, A. E.; Humphrey, C. D.; Shieh, W. J.; Guarner, J.; Paddock, C. D.; Rota, P.; Fields, B.; DeRisi, J.; Yang, J. Y.; Cox, N.; Hughes, J. M.; LeDuc, J. W.; Bellini, W. J.; Anderson, L. J. A novel coronavirus associated with severe acute respiratory syndrome N. Engl. J. Med. 2003, 348, 1953 - 1966
321. Ghosh, A. K.; Xi, K.; Ratia, K.; Santarsiero, B. D.; Fu, W.; Harcourt, B. H.; Rota, P. A.; Baker, S. C.; Johnson, M. E.; Mesecar, A. D. Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors J. Med. Chem. 2005, 48, 6767 - 6771
322. Ghosh, A. K.; Xi, K.; Grum-Tokars, V.; Xu, X.; Ratia, K.; Fu, W.; Houser, K. V.; Baker, S. C.; Johnson, M. E.; Mesecar, A. D. Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 5876 - 5880
323. Kong, J. S.; Venkatraman, S.; Furness, K.; Nimkar, S.; Shepherd, T. A.; Wang, Q. M.; Aube, J.; Hanzlik, R. P. Synthesis and evaluation of peptidyl Michael acceptors that inactivate human rhinovirus 3C protease and inhibit virus replication J. Med. Chem. 1998, 41, 2579 - 2587
324. Kim, T. S.; Hague, A. B.; Lee, T. I.; Lian, B.; Tegley, C. M.; Wang, X.; Burgess, T. L.; Qian, Y. X.; Ross, S.; Tagari, P.; Lin, C. H.; Mayeda, C.; Dao, J.; Jordan, S.; Mohr, C.; Cheetham, J.; Viswanadhan, V.; Tasker, A. S. 4-Piperidinylphenyl)aminoethyl amides as a novel class of non-covalent cathepsin K inhibitors Bioorg. Med. Chem. Lett. 2004, 14, 87 - 90
325. Barrett, D. G.; Boncek, V. M.; Catalano, J. G.; Deaton, D. N.; Hassell, A. M.; Jurgensen, C. H.; Long, S. T.; McFadyen, R. B.; Miller, A. B.; Miller, L. R.; Payne, J. A.; Ray, J. A.; Samano, V.; Shewchuk, L. M.; Tavares, F. X.; Wells-Knecht, K. J.; Willard, D. H., Jr.; Wright, L. L.; Zhou, H. Q. P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K Bioorg. Med. Chem. Lett. 2005, 15, 3540 - 3546
326. Marquis, R. W.; Ru, Y.; LoCastro, S. M.; Zeng, J.; Yamashita, D. S.; Oh, H. J.; Erhard, K. F.; Davis, L. D.; Tomaszek, T. A.; Tew, D.; Salyers, K.; Proksch, J.; Ward, K.; Smith, B.; Levy, M.; Cummings, M. D.; Haltiwanger, R. C.; Trescher, G.; Wang, B.; Hemling, M. E.; Quinn, C. J.; Cheng, H. Y.; Lin, F.; Smith, W. W.; Janson, C. A.; Zhao, B.; McQueney, M. S.; D'Alessio, K.; Lee, C. P.; Marzulli, A.; Dodds, R. A.; Blake, S.; Hwang, S. M.; James, I. E.; Gress, C. J.; Bradley, B. R.; Lark, M. W.; Gowen, M.; Veber, D. F. Azepanone-based inhibitors of human and rat cathepsin K J. Med. Chem. 2001, 44, 1380 - 1395
327. Marquis, R. W.; Ward, K. W.; Roethke, T.; Smith, B. R.; Ru, Y.; Yamashita, D. S.; Tomaszek, T. A.; Gorycki, P. D.; Cheng, H. Y.; James, I. E.; Stroup, G. B.; Lark, M. W.; Gowen, M.; Veber, D. F. An azepanone-based inhibitor of human cathepsin K with improved oral bioavailability in the rat and the monkey Mol. Pharmaceutics 2004, 1, 97 - 100
328. Barrett, D. G.; Catalano, J. G.; Deaton, D. N.; Long, S. T.; McFadyen, R. B.; Miller, A. B.; Miller, L. R.; Samano, V.; Tavares, F. X.; Wells-Knecht, K. J.; Wright, L. L.; Zhou, H. Q. Acyclic, orally bioavailable ketone-based cathepsin K inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 22 - 27
329. Thurmond, R. L.; Beavers, M. P.; Cai, H.; Meduna, S. P.; Gustin, D. J.; Sun, S.; Almond, H. J.; Karlsson, L.; Edwards, J. P. Nonpeptidic, noncovalent inhibitors of the cysteine protease cathepsin S J. Med. Chem. 2004, 47, 4799 - 4801
330. Seierstad, M.; Breitenbucher, J. G. Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors J. Med. Chem. 2008, 51, 7327 - 7343
331. Lambert, D. M.; Fowler, C. J. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications J. Med. Chem. 2005, 48, 5059 - 5087
332. Mackie, K. Cannabinoid receptors: where they are and what they do J. Neuroendocrinol. 2008, 20, 10 - 14
333. Blankman, J. L.; Simon, G. M.; Cravatt, B. F. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol Chem. Biol. 2007, 14, 1347 - 1356
334. Labar, G.; Bauvois, C.; Borel, F.; Ferrer, J. L.; Wouters, J.; Lambert, D. M. Crystal structure of the human monoacylglycerol lipase, a key actor in endocannabinoid signaling ChemBioChem 2010, 11, 218 - 227
335. Mulvihill, M. M.; Nomura, D. K. Therapeutic potential of monoacylglycerol lipase inhibitors Life Sci. 2013, 92, 492 - 497
336. Jung, K. M.; Sepers, M.; Henstridge, C. M.; Lassalle, O.; Neuhofer, D.; Martin, H.; Ginger, M.; Frick, A.; DiPatrizio, N. V.; Mackie, K.; Katona, I.; Piomelli, D.; Manzoni, O. J. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome Nat. Commun. 2012, 3, 1080
337. King, A. R.; Duranti, A.; Tontini, A.; Rivara, S.; Rosengarth, A.; Clapper, J. R.; Astarita, G.; Geaga, J. A.; Luecke, H.; Mor, M.; Tarzia, G.; Piomelli, D. URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices Chem. Biol. 2007, 14, 1357 - 1365
338. Long, J. Z.; Li, W.; Booker, L.; Burston, J. J.; Kinsey, S. G.; Schlosburg, J. E.; Pavon, F. J.; Serrano, A. M.; Selley, D. E.; Parsons, L. H.; Lichtman, A. H.; Cravatt, B. F. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects Nat. Chem. Biol. 2009, 5, 37 - 44
339. Chang, J. W.; Niphakis, M. J.; Lum, K. M.; Cognetta, A. B., III; Wang, C.; Matthews, M. L.; Niessen, S.; Buczynski, M. W.; Parsons, L. H.; Cravatt, B. F. Highly selective inhibitors of monoacylglycerol lipase bearing a reactive group that is bioisosteric with endocannabinoid substrates Chem. Biol. 2012, 19, 579 - 588
340. Hsu, K. L.; Tsuboi, K.; Chang, J. W.; Whitby, L. R.; Speers, A. E.; Pugh, H.; Cravatt, B. F. Discovery and optimization of piperidyl-1,2,3-triazole ureas as potent, selective, and in vivo -active inhibitors of alpha/beta-hydrolase domain containing 6 (ABHD6) J. Med. Chem. 2013, 56, 8270 - 8279
341. Tchantchou, F.; Zhang, Y. Selective inhibition of alpha/beta-hydrolase domain 6 attenuates neurodegeneration, alleviates blood brain barrier breakdown, and improves functional recovery in a mouse model of traumatic brain injury J. Neurotrauma 2013, 30, 565 - 579
342. Li, W.; Blankman, J. L.; Cravatt, B. F. A functional proteomic strategy to discover inhibitors for uncharacterized hydrolases J. Am. Chem. Soc. 2007, 129, 9594 - 9595
343. Bracey, M. H.; Hanson, M. A.; Masuda, K. R.; Stevens, R. C.; Cravatt, B. F. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling Science 2002, 298, 1793 - 1796
344. Lichtman, A. H.; Shelton, C. C.; Advani, T.; Cravatt, B. F. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia Pain 2004, 109, 319 - 327
345. Massa, F.; Marsicano, G.; Hermann, H.; Cannich, A.; Monory, K.; Cravatt, B. F.; Ferri, G. L.; Sibaev, A.; Storr, M.; Lutz, B. The endogenous cannabinoid system protects against colonic inflammation J. Clin. Invest. 2004, 113, 1202 - 1209
346. Huitron-Resendiz, S.; Sanchez-Alavez, M.; Wills, D. N.; Cravatt, B. F.; Henriksen, S. J. Characterization of the sleep-wake patterns in mice lacking fatty acid amide hydrolase Sleep 2004, 27, 857 - 865
347. Varvel, S. A.; Wise, L. E.; Niyuhire, F.; Cravatt, B. F.; Lichtman, A. H. Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task Neuropsychopharmacology 2007, 32, 1032 - 1041
348. Tarzia, G.; Duranti, A.; Tontini, A.; Piersanti, G.; Mor, M.; Rivara, S.; Plazzi, P. V.; Park, C.; Kathuria, S.; Piomelli, D. Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors J. Med. Chem. 2003, 46, 2352 - 2360
349. Alexander, J. P.; Cravatt, B. F. Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes Chem. Biol. 2005, 12, 1179 - 1187
350. Gattinoni, S.; Simone, C. D.; Dallavalle, S.; Fezza, F.; Nannei, R.; Battista, N.; Minetti, P.; Quattrociocchi, G.; Caprioli, A.; Borsini, F.; Cabri, W.; Penco, S.; Merlini, L.; Maccarrone, M. A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase Bioorg. Med. Chem. Lett. 2010, 20, 4406 - 4411
351. Butini, S.; Brindisi, M.; Gemma, S.; Minetti, P.; Cabri, W.; Gallo, G.; Vincenti, S.; Talamonti, E.; Borsini, F.; Caprioli, A.; Stasi, M. A.; Di Serio, S.; Ros, S.; Borrelli, G.; Maramai, S.; Fezza, F.; Campiani, G.; Maccarrone, M. Discovery of potent inhibitors of human and mouse fatty acid amide hydrolases J. Med. Chem. 2012, 55, 6898 - 6915